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Recombinant human spasmolytic polypeptide (r-hSP) has been produced in relatively large amounts in Succharomyces cerevuiae. The two intronless 
trefoil domains of the hSP-DNA were cloned separately by PCR from human genomic DNA, and the remaining parts of the gene syntheztsed. 
Recombinant plasmids were constructed to encode a fusion protein consisting of a hybrid leader sequence and the hSP sequence. The leader sequence 
serves to direct the fusion protein into the secretory pathway of the cell and to expose it to the Kex 2 processing enzyme system. The secreted r-hSP 
was found in a glycosylated and an non-glycosylated form. The two forms of r-hSP were purified from the yeast fermentation broth by a combination 
of ion-exchange chromatography and preparative HPLC. The overall yield from 8 litres of fermentation broth was 160 mg r-hSP and 219 mg 
glycosylated r-hSP corresponding to 50% and 34%. respecttvely. The structure of the r-hSP and the glycosylated r-hSP was determined by amino 
acid analysis and carbohydrate composition analysis as well as by peptrde mapping, amino acid sequencing and mass spectrometrtc analysis. 
Pancreatic spasmolytic polypeptide; Spasmolyttc polypepttde; Intestinal trefoil factor; Intestinal trefoil factor; Breast cancer associated peptide; 
Breast cancer associated peptide (pS2); N-Glycosylatton; Electra-spray mass spectrometry 
1. INTRODUCTION 
Human spasmolytic polypeptide (hSP) belongs to a 
growing family of peptides containing one or more 
characteristic trefoil domains [l]. The trefoil domain is 
made up by a sequence of 38 or 39 amino acid residues 
in which 6 cysteine residues are linked in the configura- 
tion l-5, 24 and 3-6 thus forming a characteristic 
three-leaved structure [l]. The trefoil family of peptides 
consists of rat intestinal trefoil factor, ITF [2], human 
breast cancer associated peptide, pS2 [3-51, spasmolytic 
polypeptide from pig, human and mouse (PSP, hSP, 
mSP) [6-81 and frog spasmolysins (xP1, xP2 and xP4) 
[&lo, 1 l] all containing 1, 2 or 4 trefoil domains (Fig. 1). 
The physiological function of the trefoil peptides is 
poorly understood, and so far only PSP has been stud- 
ied in some detail. In the porcine pancreas, PSP is found 
in the acinar cells and is secreted in large amounts 
(50-100 mg/ml) into the pancreatic juice upon stimula- 
tion with pancreozymin or secretin [12-141. PSP is resis- 
tant towards digestion by intestinal proteases within the 
gastrointestinal tract [12], and specific binding of PSP 
to rat intestinal mucosa cells and membrane prepara- 
tions from these cells have been demonstrated [15,16]. 
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In the porcine gastrointestinal tract, specific receptor- 
like binding to Paneth cells in the duodenum has been 
found [ 171. These results suggest a unique intraluminal 
function of the peptide. A pharmacological screening 
has indicated that PSP has spasmolytic and gastric acid 
secretion inhibitory effects [18], and studies on mam- 
malian cells have indicated a growth factor-like activity 
of PSP [19]. 
In contrast to porcine PSP, the human counterpart, 
hSP (Fig. 2). has been found to be expressed in the 
stomach, but not in the pancreas to any great extent 
[8]. An increased expression of hSP and pS2 has been 
reported in association with peptic ulcers and mucosal 
injury in inflammatory bowel disease [20,21] indicating 
a possible healing function of these peptides. 
Only very limited amounts of hSP can be prepared 
from human tissue extraction, and in the present study, 
we describe a yeast expression system designed for the 
production of sufficient amounts of hSP for physiologi- 
cal and biochemical studies of the peptide. 
2. MATERIALS AND METHODS 
2.1. General methods 
Standard DNA techniques were used as previously described [29]. 
Synthetic oligonucleotides were prepared on an automatic DNA syn- 
thesizer (380B, Applied Biosystems) usmg commercially available rea- 
gents. DNA sequence determinations were performed by the dideoxy 
chain-termination technique [30]. Polymerase chain reactions (PCR) 
were performed on a DNA Thermal Cycler (Perkin Elmer Cetus) 
using a commercial kit (GeneAmp, Perkin Elmer Cetus). 
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2.2. PCR cloning of hSP 
The first trefoil domain of hSP was isolated by a PCR reaction m 
which 1 pg human genomic DNA (Clontech, Palo Alto, CA, USA) 
was used as a template. The reaction mixture contained 100 pmol each 
of the forward primer 1 (GGCTGAGCCCCCATAACAG) and re- 
verse primer 2 (TGGAAACACCAGGGGAC) (Fig. 3) and was car- 
ried out in a 100 ~1 volume. The cycle was: 94*C for 1 min, 50°C for 
1 min, and 72°C for 1 min. After 30 cycles a final cycle was performed 
m which the 72°C step was maintained for 10 min. The PCR product, 
a 115 bp fragment, was isolated by electrophoresis on a 2% agarose 
gel. 
The 115 bp PCR fragment was digested with D&I and then ligated 
to a 31 bp duplex formed from the oligonucleotides (GAGAAA- 
CCCTCCCCCTGCCAGTGCTCCAGGC) and (TCAGCCTGGAG- 
CACTGGCAGGGGGAGGGTTTCTC). The ligation product was 
amplified by PCR using forward primer 3 (GCTGAGAGATTGGA- 
GAAGAGAGAGAAACCCTCCCCCT~ and reverse primer 2. The 
3’ part of primer 3 1s identical to the N-terminal encoding part of the 
hSP gene and the 5’ part of primer 3 is identical to the C-terminal 
encoding part of the hybrid leader gene (Fig. 3). 
In-frame fusion of the hybrid leader gene and the first trefoil domain 
from hSP was obtained by overlay extension PCR [31]. The product 
was digested with EroRI and AvaII and isolated as a 360 bp DNA 
fragment. 
The second trefoil domain of hSP was PCR-cloned from human 
genomtc DNA as described for the first domain by replacing pnmers 
1 and 2 with forward primer 4 (TGCGTCATGGAGGTCTC) and 
reverse primer 5 (AGCACCATGGCACTTCAAAG) (Fig. 3). Re- 
verse primer 5 introduces a NeoI site as a silent mutation. The PCR 
product, a 115 bp fragment, was isolated and digested with DdeI and 
NcoI resulting in a 91 bp fragment. To this fragment was hgated two 
synthetic duplexes. The first, encoding the amino acid sequence be- 
tween the two trefoil domains, consisted of the oligonucleotides 
(GTCCCCTGGTGTTTCCACCCCCTCCCAAAGCAAGAGTCG- 
GATCAGTGCGTCATGGAGGTC) and (TGAGACCTCCAT- 
GACGCA~GATCCGACTffTG~G~AGGGGGTGGAA- 
ACACCAGGG). The second, a 46 bp N&-X&I fragment encoding 
the C-terminal part of hSP, consisted of the oligonucleotides 
(CATGGTGCTTCTTCCCGAACTCTGTGGAAGACTGCCATT- 
ACTAAGT) and (CTAGACTTAGTAATGGCAGTCTTCCAC- 
AGAGTTCGGGAAGAAGCAC). After AnzII digestion a 195 bp 
AvaII-X&I fragment was isolated. 
A DNA construct encoding the hybrtd leader fused in-frame to the 
entire hSP gene was obtained by ligation of the 360 bp EcoRI-AvaII 
fragment and the 195 bp AvaII-X&I fragment descnbed above to the 
2.7 kb EeoRI-X&I fragment from vector pTZ19R 1321. This construct 
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Fig. 1. Trefoil family of peptides. Intestinal trefoil factor (ITF) con- 
tams one trefoil domain 121, as does the breast cancer associated pS2 
peptide 13.41. The spasmolytic polypeptides from man, pig and mouse 
contain two trefoil domains [1,8]. Spasmolysins from Xenopus Iuevis 
contam one or four trefoil domains [lo]. Recently, a member of the 
frog trefoil family containing two domains has been described [I I]. 
was then transformed into E. co11 strain MT-172 (r-, m’) by selectton 
for resistance to ampicillin. DNA sequencing of the resulting plasmid, 
KFN-1843, showed that the correct construction had been obtained. 
2.3. Construction of the hSP secreting yeast strain 
Plasmid KFN-1843 described above was digested with EcoRI and 
X&I. The resulting 558 bp fragment was isolated and ligated to the 
9.3 kb NcoI-X&I fragment and the 1.6 kb NcoI-EcoRI fragment both 
from the yeast expression vector pMT-636. Plasmid pMT-636 is de- 
rived from the S cerevisroe-E coii shuttle vector CPOT 125,331 by 
deletion of the 0.4 kb HpaI-NruI fragment from the Leu-2 gene. The 
ligation mixture was transformed mto E. coli strain MT-172, and the 
hSP expression plasmid, KFN-1847, was isolated (Ftg 4). Plasmid 
pKFN-1847 was transformed into S cerevisiae strain MT-663 by 
selection for growth on glucose as the sole carbon source. One trans- 
formant, KFN-I 852, was selected for fermentation. 
2.4. Fermentation 
The transformant described above was cultivated at 30°C for 3 days 
in yeast peptone dextrose (YPD) medium [40] supplied with additional 
yeast extract (60 g/l). An OD 650 nm value of 52 was reached at the 
end of the fermentation. 
2.5. Pur$catton of r-hSP 
The concentration of r-hSP in the yeast fermentation broth and 
fractions obtamed during the puri~cation was measured by analytical 
HPLC. Aliquots (usually 50-200 ~1) were injected onto a Vydac 
214TP54 reverse-phase C4 HPLC column (0.46 x 25 cm) equilibrated 
at 30°C at a flow rate of 1.5 mYmin with 0.1% (v/v) TFA in 5% (v/v) 
acetonitrile. The concentration of acetonitrile in the elutmg solvent 
was raised to 65% (v/v) over 30 min. Absorbance was measured at 280 
nm. The peaks eluting at 15.6 min. and 16.1 mm. (Fig. 5) was found 
by mass spectrometry analysts to represent glycosylated r-hSP and 
unglycosylated r-hSP, respecttvely. The peptides were quantified using 
a calibrated PSP sample as standard as both peptides contain two Trp 
and two Tyr out of 106 amino acid residues. 
From a 10 1 fermentor, 8 1 of fermentation broth was isolated 
by centrifugation at 3,000 rpm for 10 min. The supernatant was con- 
centrated to 0.9 1 using an Amicon ultrafiltration unit (RA 2000) 
equipped with an Amicon spiral ultrafiltration cartridge type SlY3, 
MW cutoff 3.000 (Product No. 540620). The pH was adjusted to 1.7 
and the conductivity m the resulting concentrated sample was meas- 
ured to 4.7 mS. 
The sample was pumped onto a Fast Flow S-Sepharose (Pharmacta) 
column (5 x 11 cm) with a Row rate of 40 ml/h. Previous to the 
appllcatlon, the column was equilibrate in 50 mM formic acid buffer, 
pH 3.7. After application of the sample. the column was washed with 
500 ml of 50 mM formic acid buffer. pH 3.7. The peptides were eluted 
from the column by a linear gradient between 1.5 I of 50 mM 
formic acid buffer, pH 3.7, and 1.5 1 of 50 mM formic acid buffer, 
pH 3.7, containmg 0.6 M NaCl. Fractions of 10 ml were collected at 
a flow rate of 40 ml/h and the absorbance was measured at 280 nm. 
Fractions were assayed for the content of r-hSP and glycosylated 
r-hSP m the HPLC-system as previously described. The elution profile 
is shown in Fig. 6. Fractions corres~ndin~ to r-hSP (fract. nos. 
107-128) and glycosylated r-hSP (fract. nos. 78-95) respectively. were 
pooled. 
Glycosylated r-hSP and r-hSP were further purified by preparative 
HPLC chromatography. Pooled fractions (approx. 200 ml) were 
pumped onto a Vydac 214TP1022 C4 column (2.2 x 25 cm) equili- 
brated in 0.1% (v/v) TFA. The column was washed with 100 ml of 
0.1% (v/v) TFA in 10% (v/v) MeCN. The peptides were eluted at 25°C 
and at a flow rate of 5 mllmin with a hnear gradtent (650 ml) formed 
from MeCN/H20/TFA (10.0 : 89.9 : 0.1 v/v/v) and MeCN/H~O/TFA 
(60.0 : 39.9 : 0.1 v/v/v). UV-abso~tion was monitored at 280 nm, and 
fractions corresponding to 10 ml were collected and analysed for the 
content of r-hSP or glycosylated r-hSP. Fig. 7 shows the preparattve 
HPLC purification of r-hSP (Fig. 7A) and glycosylated r-hSP (Fig. 
7B). Fractions correspondmg to the bars were pooled, and the volume 
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reduced to 30% by vacuum centrifugation. From the two resulting 
pools, r-hSP and glycosylated r-hSP were isolated by lyophilization. 
2.6. Characterization of r-hSP and glycosylated r-hSP 
Amino acid composition analysis were carried out by hydrolysis of 
50 pug peptide with 6 M HCI for 24 h at 110°C as previously described 
[6]; no correction for loss during hydrolysis was carried out. Amino 
acid sequence analysis was determined by automated Edman degrada- 
tion using an Applied Biosystems Model 470A gas-phase sequencer 
[22]. Carbohydrate composition analysis was carried out by hydrolysis 
of 50 pg peptide with 2 M HCI for 1 h, 2 h and 4 h at 100°C and 
monosaccharides were separated on a CarboPac PAI (Dionex, Sun- 
nyvale, CA) column (4 x 250 mm) eluted with 14 mM NaOH. The 
monosaccharides were detected by pulsed amperometric detection 
(Dionex PAD-detector). The amount of monosaccharides was cor- 
rected to zero time of hydrolysis and calculated as nmol of monosac- 
charide per nmol of peptide. 
Mass spectrometry analysis was performed using an API III LC/ 
MS/MS system (Sciex, Thornhill, Ont., Canada). The triple quad- 
rupole instrument has a mass-to-charge (m/e) range of 2400 and is 
fitted with a pneumatically assisted eiectrospray (also referred to as 
ion-spray) interface [23,24]. Sample introduction was done by a sy- 
ringe infusion pump (Sage Instruments, Cambridge, MA) through a 
fused capillary (7.5 pm id.) with a liquid flow-rate set at 0.5-l @/min. 
The instrument m/z scale was calibrated with the singly-charged am- 
monium adduct ions of poly(propylene glycols) (PPGs) under unit 
resolution. 
The accuracy of mass measurements is generally better than 0.02%. 
Fig. 2. Proposed structure of human spasmolytic polypeptide, hSP. The primary amino acid sequence is taken from Tomasetto et al. [8], and the 
disulphide bonds are placed in homology to PSP [I]. 
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EcoRI 
GAATTCCATTCAAGAATAGTTCAAACAAGAAGATTACAAAT 
ATAAACGACCAAAAGAATGAGCTGTTTTCTTGGTTTTGTCCTTGATCGGATTCTGCTG 
MKAVFLVLSLIGFCW 
GGCCCAACCAGTCACTGGCGATGAATCAT2TGTTGAGATTTCAT 
A Q PVTGDESSVEI PEESLII 
CGCTGAAAACACCACTTTGGCTAACGTCGTCGCCATGGCTGAGAGATTGGAG~GAGAgagaa 
AENTTLANVAMAER LEKREK 
I Dde 1, t 
accctccccctgccagtgctccaaacTGAGCCCCCATAACCTGCGGCTTCCC 
PSPCQCSRLS PHNRTNCGFP 
TGGAATCACCAGTGACCAGTGTTTTGACAATGGATGGATGCTGTTTCGACTCCAGTGTCACTGG 
G I T S D Q C FDNGCCFDSSVTG 
AvaII ,2 4, 
Gatcccctaatatttccaccccctcccaaagcaagagtcggatcagtacatcatggaggt 
VPWCFHPLPKQ E S D Q C V M E V 
Dde I 
cTCAGACAGAAGAAACTGTGGCTACCCGGGCATCAGCCCCGAGG~TGCGCCTCTCGG~ 
SDRRNCGYPGI SPEECASRK 
,5 Nco I 
GTGCTGCTTCTCCAACTTCATCTTTGAAGTGCcatagtgcttcttcccgaactctgtgga 
CCFSNFI FEVPWC FFPNSVE 
Xba I 
agactgccattactaagtCTAGA 
D C H Y 
Fig. 3. Nucleotide sequence and corresponding ammo acid sequence of the 563 bp EcoRI-X&I fragment encodmg the leader hSP fusion protein. 
The Kex 2 processing site is indicated by a vertical arrow. The leader and the PCR cloned parts of the hSP gene are shown in capital letters, while 
the synthetic parts are shown in small letters. The underlined sequences correspond to the PCR primers with horizontal arrows Indicating the 
direction. Restriction sites relevant for the construction are shown. 
3. RESULTS 
3.1. Expression and puriJication 
DNA fragments encoding the two trefoil domains of 
hSP were isolated by PCR from human genomic DNA 
using primers based on the published cDNA sequence 
[8]. The full-length hSP gene was obtained from the 
PCR cloned fragments by addition of synthetic DNA 
fragments. The hSP gene was fused in-frame to a hybrid 
hSP expression vector 
Fig. 4. S cerer~~~e plasmid for the expression and secretion of hSP. 
TPI-prom. and TPI-term. are S. cerrvinae triosephosphate isomerase 
transcription promoter and terminator sequences, respectively. POT 
is a selective marker, the Schl~osuccl~aror,~~ces ponzbe triosephosphate 
isomerase gene. Only restriction sites relevant for the construction of 
the plasmid have been indicated. 
yeast leader sequence by overlay extension PCR [31] 
(Fig. 3). The hybrid leader is based on the mouse sali- 
vary amylase signal peptide [34] and the S. kluyveri 01 
mating factor leader sequence [35] and is further modi- 
fied near the Kex 2 cleavage site for efficient processing 
[36,41]. 
The yeast expression plasmid pKFN-1847 contains 
the leader-hSP gene inserted between the S. cerevisiae 
triosephosphate isomerase promoter and terminator 
[37]. The expression vector (Fig. 4) also contains the 
Schizosaccharomyces pombe TPI gene (POT) [38]. 
The plasmid was transformed into the yeast strain 
MT-663, carrying a deletion in the TPI gene, by select- 
ing for growth on glucose. 
The expression level of r-hSP in the present yeast 
system is approx. 120 mg/l. This is 10 times higher than 
what we have previously obtained with different insulin 
precursors in a similar system [25]. However, the pres- 
ent yeast cells were grown on a complex medium in a 
fermentor as compared to the insulin precursor produc- 
ing yeast cells which were grown on a minimal medium 
in shake flasks. As can be seen from Fig. 5, the yeast 
supernatant contains two forms of r-hSP: one eluting at 
R, = 15.6 min. and one eluting at R, = 16.1 min. These 
two forms were purified separately, and by using the 
analytical HPLC-system (Fig. 5) these two forms can 
be quantified individually during the different steps of 
the purification. 
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Fig. 5. Reversed-phase HPLC on a Vydac 214TP54 column of yeast 
fermentation broth. The two peaks corresponding to r-hSP and glyco- 
sylated r-hSP are indicated. The dashed line shows the concentration 
of acetonitrile in the eluting solvent. 
After the initial concentration of the yeast superna- 
tant by ultrafiltration, the first purification step was 
cationic exchange chromatography on a Fast Flow S 
column. Fig. 6 shows the elution profile from the col- 
umn including the amount of r-hSP and glycosylated 
r-hSP determined in the fractions. A complete separa- 
tion of the two forms of r-hSP was obtained in this step. 
The fractions from the Fast Flows S column were 
pooled as indicated in Fig. 6, and the two peptides were 
further purified by preparative HPLC (Fig. 7). The r- 
hSP and glycosylated r-hSP were recovered from the 
fractions indicated in Fig. 7A and B by vacuum centrif- 
ugation and lyophilization. The purification is sumrna- 
rized in Table I. The overall yield of r-hSP and glycosyl- 
ated r-hSP from 8 litres of fe~entation broth was 160 
mg and 219 mg corresponding to 50% and 34%, respec- 
tively. 
P 
-3 a 
E 
E 
C 6- -06 
Fraction no. (vol. = 10 ml) 
Fig. 6. Ion exchance chromatography on a Fast Flow S column of 
concentrated yeast supernatant. The amount of r-hSP and glycosyl- 
ated r-hSP were determined by the use of the HPLC system shown in 
Fig. 5. The bars indicate the fractions pooled for further purification 
of r-hSP and glycosylated r-hSP. The dashed line shows the concentra- 
tion of NaCl in the eluting solvent. For details, see Materials and 
Methods. 
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Fig. 7. Final purification of r-hSP (A) and glycosylated r-hSP (B) on 
a preparative reversed-phase HPLC Vydac 214TP1022 column. The 
bars indicate the fractions pooled for lyophil~ation. The dashed lines 
show the con~ntration of acetonitrile in the eluting solvent. For 
details, see Materials and Methods, 
3.2. Characterization of r-hSP and glycosylated r-hSP 
Fig. 8 shows the purity of r-hSP and glycosylated 
r-hSP as analysed by analytical HPLC. From these re- 
sults none of the peptides looks completefy pure. How- 
ever, upon rechromatography of material eluting in the 
minor as well as the major peak, similar chromatograms 
were obtained for both peptides (results not shown). 
This seems to indicate that the double peak observed for 
both r-hSP and glycosylated r-hSP reflects an atypical 
behaviour of these peptides on reverse phase columns 
rather than impurities in the preparations. We have 
previously observed a similar behaviour of highly puri- 
fied porcine PSP on reverse phase columns (L. Thim 
and K.H. Jorgensen, unpublished observations). 
Table II shows the amino acid sequencing results 
obtained on r-hSP and glycosylated r-hSP. The average 
repetitive yield was 94.4% (r-hSP) and 94.6% (glycosyl- 
ated r-hSP), respectively. In both cases the first 40 resi- 
dues of the two peptides were confirmed by the sequence 
analysis. In the glycosylated hSP, no PTH-amino acids 
was found in Edman degradation cycle No. 15. The hSP 
sequence from residue 15-17 (Asn-Arg-Thr) corre- 
sponds to a classical consensus equence for N-glycosyl- 
ation of Asn-15. 
The carbohydrate composition analysis of glysocyl- 
ated r-hSP showed the presence of 12.8 nmol mannose 
349 
Volume 318, number 3 FEBS LETTERS March 1993 
Table I 
Purification of r-hSP and glycosylated r-hSP from yeast supernatant 
Step Volume 
(ml) 
Amount (mg) 
r-hSP Glycosylated 
r-hSP 
Yield (%) 
r-hSP Glycosylated 
r-hSP 
Yeast supernatant 
Ultrafiltration 
Ion exchange chromatography 
Pool 1 
Pool 2 
Prep HPLC 
Pool 1 
Pool 2 
8000 320 640 100 100 
900 207 40.5 65 63 
160 275 43 
220 182 51 
54 219 34 
80 160 50 
(Man) and 1.6 nmol of N-acetyl glucoseamine 
(GlcNAc) per nmol of r-hSP. By peptide mapping of 
r-hSP and glycosylated r-hSP in combination with mass 
spectrometry and sequencing analysis (results not 
shown), no other residue besides Asn-15 of the glycosyl- 
ated r-hSP was found to be modified, i.e. no O-glycosyl- 
ation was found. 
In Fig. 9, the electro-spray mass spectrometry 
(ESMS) analysis is shown for r-hSP and glycosylated 
r-hSP. Fig. 9A and C are original mass spectra display- 
ing characteristics series of multiply charged protonated 
ions always observed in ESMS spectra of proteins. Fig. 
9B and D are the corresponding computer recon- 
structed mass spectra from which the molecular weight 
of individual components may be read directly. As can 
be seen from Fig. 9B, the MW found for r-hSP is 
11 961.5 ? 2 which is in very good agreement with a 
calculated mass of 11 961.3. Fig. 9D shows the recon- 
structed ion spray mass spectrum of the glycosylated 
r-hSP. From the sequence analysis and the carbohy- 
drate composition analysis, it is known that only Asn- 
d 5 lb 1; 20 25 
Time (mm) 
Fig. 8. Reversed-phase HPLC on a Vydac 214TP54 column of puri- 
fied, glycosylated r-hSP (A) and r-hSP (B). The dashed lines show the 
concentration of acetonitrile in the elutmg solvent. 
Table II 
Amino acid sequence analysis of r-hSP and glycosylated r-hSP 
Yield (pmol) 
Cycle no. PTH-amino acid r-hSP Glycosylated 
r-hSP 
1 Glu 4304 8853 
2 LYS 6925 8292 
3 Pro 6027 12837 
4 Ser 2890 5602 
5 Pro 4336 8802 
6 (CYSI ND ND 
7 Gin 3388 5689 
8 CCYS) ND ND 
9 Ser 1279 2417 
10 Arg 1876 2523 
II Leu 2271 4290 
12 Ser 817 1790 
13 Pro 1545 2963 
14 His 517 574 
15 Asn 1202 0* 
16 Arg 959 1471 
17 Thr 978 2172 
18 Asn 1066 1509 
19 (CYS) ND ND 
20 GUY 836 1857 
21 Phe 993 1958 
22 Pro 843 1839 
23 GUY 785 2049 
24 Ile 640 1400 
25 Thr 589 1454 
26 Ser 274 621 
27 Asp 581 1391 
28 Gln 445 952 
29 (CYS) ND ND 
30 Phe 623 1562 
31 Asp 483 1210 
32 Asn 369 823 
33 GUY 359 885 
34 (CYS) ND ND 
35 (CYS) ND ND 
36 Phe 422 1094 
37 Asp 268 783 
38 Ser 127 324 
39 Ser 145 394 
40 Val 298 827 
ND = not determined. * = no trace of PTH-Asn or PTH-Asp was seen 
in cycle No. 15 of glycosylated r-hSP. 
350 
0 _II, 0 t 
7 1 so 11,950 12.000 12,050 14.cm 14.*00 14,4rJo 14.600 14.800 15.ocm 
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Fig. 9. Mass spectra of purified r-hSP (A and B) and glycosylated r-hSP (C and D). A and C show the original mass spectrum of r-hSP and 
glycosylated r-h%‘, respectively. B and D show the reconstructed mass spectrum for r-hSP and glycosylated r-hSP on the basis of A and C. 
15 is glycosylated and that only two monosaccharide Initial attempts to clone the entire hSP gene by PCR 
residues, mannose and N-acetyl glucoseamine, occur in from human genomic DNA were not successful. One 
the glycosylated form of r-hSP. From these results in explanation for this could be the presence of introns of 
combination with the mass spectrometry data, it is pos- unknown size flanking each trefoil domain. In the 
sible to deduce the different glycosylated forms of r-hSP human oestrogen-responsive g ne pS2 the single trefoil 
(Table III). domain is flanked by 3 kb and 0.8 kb introns [39]. 
Molecular weights corresponding to two series of car- 
bohydrate side chains can be deduced from the combi- 
nation of carbohydrate composition data and ISMS- 
data, namely (GlcNAc),(Hex),,,, and (Hex),,,, (Table 
III). As mannose is the only hexose in the glycosylated 
r-hSP, and as Asn-15 is the only glycosylated residue, 
it seems reasonable to conclude that the structure of the 
glycosylation site is Asn-(GlcNAc),-(Man),,,,. The ob- 
served Asn-(Hex),,_,, forms are thus most likely to arise 
from fra~entation in the mass spectrometre, by which 
the two GlcNAc residues lose an acetyl group and are 
converted into two hexoses. 
Due to the high level of expression, the purification 
of the yeast produced hSP is relatively simple resulting 
in an overall purification yield of 50% and 34% for 
r-hSP and glycosylated r-hSP, respectively. The primary 
amino acid sequence of the r-hSP was shown by auto- 
mated Edman degradation, peptide mapping and mass 
Table III 
Mass analysis of glycosylated r-hSP 
The structure of Asn-(GlcNAc),-(Man),a-,, has previ- 
ously been reported as high mannose type of N-glyco- 
sylation for other peptides and proteins expressed in 
yeast [26]. 
Structure Calculated M.W. found by 
M.W. ESMS (Fig. 9D) 
4. DISCUSSION 
hSP + 2 GlcNAc + 10 Man 13,989.l 13,989s 
hSP + 2 GlcNAc + 11 Man 14,151.2 14,151.0 
hSP + 2 GlcNAc + 12 Man 14.313.4 14.313.5 
hSP + 2 GlcNAc + 13 Man 14.4755 14,475.0 
hSP + 2 GlcNAc + 14 Man 14,639.7 14,639.5 
hSP + 2 GlcNAc + 15 Man l4,799.8 14,801.5 
In the present study, we describe the application of 
a yeast expression system for the production of mg to 
g amount of r-hSP. The hSP gene was constructed by 
a combination of PCR cloning of each of the two in- 
tronless trefoil domains and synthetic DNA chemistry. 
hSP + 13 Man 
hSP + 14 Man 
hSP + 15 Man 
hSP + 16 Man 
hSP + 17 Man 
14,069.l 14.072.0 
14,231.3 14.232.5 
14,393.4 14,393.0 
14,555s 14.557.5 
14,717.7 14,720.O 
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spectrometry analysis to be identical to the sequence of 
hSP derived from cDNA sequencing previously de- 
scribed [8]. In the yeast-expressed hSP, the N-terminal 
amino acid residue is glutamic acid in contrast to the 
natural occurring porcine PSP in which the N-terminal 
~utamine has cyclized to pyrrolidone carboxylic acid 
[f7]. It is not known if the N-terminal residue of natu- 
rally occurring hSP is glutamic acid or pyrrolidone car- 
boxylic acid. 
No free SH-groups were found in r-hSP indicating 
that all 14.5 Cys-residues form disulphide bonds. The 
secondary structure of hSP including the seven di- 
sulphide bonds (Fig. 2) has been placed by homology 
to porcine PSP [I]. Final proof of the disulphide bond 
configuration in hSP as well as PSP may come from 
3-dimensional structure analysis by X-ray [27] or NMR 
v31. 
The yeast-expressed r-hSP is secreted as two different 
forms into the culture media; one form is N-glycosyl- 
ated at Asn- 15, the structure being a high mannose form 
of Asn-(~lcNAc}*-(Man),~,~; the other form of r-hSP 
is non-glycosylated. The two forms are secreted from 
the yeast cell in the ratio of 2: 1. In man, hSP is expressed 
in normal stomach epithelium [8] and probably secreted 
into the gastric juice. However, as the peptide has not 
been purified and characterized on protein level, it is not 
known whether or not the naturally occurring hSP is 
glycosylated. The biological function of hSP as well as 
other members of the trefoil family (PSP, ITF, pS2, frog 
skin peptides) are poorly understood so far. As hSP is 
difficult to purify in any significant amount from tissue 
extraction and extremely difficult to obtain by peptide 
synthesis, the yeast expression system described in the 
present study may become a valuable tool in obtaining 
pure peptide for physiological and pathophysiological 
studies. 
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